AbbVie Total Non-Cash Items 2010-2025 | ABBV
AbbVie annual/quarterly total non-cash items history and growth rate from 2010 to 2025. Total non-cash items can be defined as the total of all non-cash charges adjusting Net Income on the Cash Flows Statement
- AbbVie total non-cash items for the quarter ending March 31, 2025 were $17.365B, a 12.92% increase year-over-year.
- AbbVie total non-cash items for the twelve months ending March 31, 2025 were $36.494B, a 10.62% decline year-over-year.
- AbbVie annual total non-cash items for 2024 were $17.365B, a 12.92% increase from 2023.
- AbbVie annual total non-cash items for 2023 were $15.378B, a 15.26% increase from 2022.
- AbbVie annual total non-cash items for 2022 were $13.342B, a 5.29% increase from 2021.
AbbVie Annual Total Non-Cash Items
(Millions of US $) |
| 2024 |
$17,365 |
| 2023 |
$15,378 |
| 2022 |
$13,342 |
| 2021 |
$12,672 |
| 2020 |
$11,997 |
| 2019 |
$6,850 |
| 2018 |
$7,273 |
| 2017 |
$4,558 |
| 2016 |
$2,387 |
| 2015 |
$1,398 |
| 2014 |
$2,129 |
| 2013 |
$1,447 |
| 2012 |
$1,625 |
| 2011 |
$2,108 |
| 2010 |
$1,664 |
| 2009 |
$227 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$306.016B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
